Global health impact: A basis for labeling and licensing campaigns?

Developing World Bioethics 12 (3):121-134 (2012)
Most of the world's health problems afflict poor countries and their poorest inhabitants. There are many reasons why so many people die of poverty-related causes. One reason is that the poor cannot access many of the existing drugs and technologies they need. Another, is that little of the research and development (R&D) done on new drugs and technologies benefits the poor. There are several proposals on the table that might incentivize pharmaceutical companies to extend access to essential drugs and technologies to the global poor.1 Still, the problem remains – the poor are suffering and dying from lack of access to essential medicines. So, it is worth considering a new alternative. This paper suggests rating pharmaceutical and biotechnology companies based on how some of their policies impact poor people's health. It argues that it might be possible to leverage a rating system to encourage companies to extend access to essential drugs and technologies to the poor
Keywords poverty  developing countries  developing world bioethics  health  pharmaceutical  essential medicines  neglected disease
Categories (categorize this paper)
DOI 10.1111/j.1471-8847.2011.00314.x
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history
Request removal from index
Download options
Our Archive

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 27,590
Through your library
References found in this work BETA

No references found.

Add more references

Citations of this work BETA
The Human Right to Health.Nicole Hassoun - 2015 - Philosophy Compass 10 (4):275-283.

Add more citations

Similar books and articles
Poverty, Disease, and Medicines in Low- and Middle-Income Countries.Klaus M. Leisinger - 2012 - Business and Professional Ethics Journal 31 (1):135-185.
Corporate Responsibilities for Access to Medicines.Klaus M. Leisinger - 2009 - Journal of Business Ethics 85 (1):3 - 23.

Monthly downloads

Added to index


Total downloads

19 ( #258,456 of 2,168,195 )

Recent downloads (6 months)

1 ( #346,757 of 2,168,195 )

How can I increase my downloads?

My notes
Sign in to use this feature

There  are no threads in this forum
Nothing in this forum yet.

Other forums